PGP Farmer, the French biotech developing what it describes as the country’s first EU-GMP medical cannabis production site, has launched a proof-of-concept phenotyping programme in the Netherlands, testing 30 cannabis genotypes from its own genetic library to determine which varieties will be cultivated at its Dordogne facility.
France’s five-year medical cannabis pilot closed on 31 March 2026, replaced by a permanent pharmaceutical-style regime overseen by the ANSM.
BofC Intelligence EU Cannabis Regulation 2026: Country Laws, Markets & Policy | Business of Cannabis Tracking legal status, market access, and regulatory developments across 28 European countries — with market data from Prohibition Partners.
View the Regulation Hub Now →
Domestic producers aiming to supply that market need validated, standardised strains before scaling. Now, PGP Farmer says it is the only French operator positioned in the production of raw pharmaceutical materials for medical cannabis (MPUP).
The three-phase programme runs in partnership with Innexo BV, a Dutch applied research platform licensed to conduct cannabis trials, which will help provide the experimental infrastructure and analytical capability.
On the PGP Farmer side, the programme is led by Frédéric Lota, Chief Scientific Officer, a Doctor of Plant Biology with 15 years of applied R&D experience. Results will directly determine cultivation and processing protocols at the company’s 9-hectare Dordogne site, where a building permit has been granted, and long-term production capacity is projected to be 30 tonnes once operational.
“We do not select our varieties randomly,” said Brahim Sebart, Co-founder and Chief Executive Officer of PGP Farmer. “This POC tests 30 genotypes under rigorous conditions to retain only those that will guarantee patients a reliable, standardised and reproducible treatment.”
European demand for medical cannabis is growing at more than 20% per year, yet approximately 75% of EU flowers still arrive from outside the continent. Germany, the largest European market, imported close to 200 tonnes in 2025; France’s geographic proximity positions PGP Farmer as a natural candidate for that export demand.
The company has moved at pace since closing a €3 million funding round in February 2026 and contributing to the joint dossier submitted to the Haute Autorité de Santé in support of a full French medical cannabis rollout.
PGP Farmer is a sponsor of next week’s Cannabis Europa London 2026, and its progress in the rapidly evolving French medical cannabis market is set to be a key point of conversation.
26–27 May 2026 · Barbican, London Cannabis Europa Two days of policy, capital and clinical strategy at the Barbican — convening operators, investors, regulators and clinicians from across the European cannabis market.
Get Your Ticket Now →
The post PGP Farmer Launches 30-Variety Dutch Trial to Set Dordogne Production Blueprint appeared first on Business of Cannabis.
Continue reading...
France’s five-year medical cannabis pilot closed on 31 March 2026, replaced by a permanent pharmaceutical-style regime overseen by the ANSM.
BofC Intelligence EU Cannabis Regulation 2026: Country Laws, Markets & Policy | Business of Cannabis Tracking legal status, market access, and regulatory developments across 28 European countries — with market data from Prohibition Partners.
View the Regulation Hub Now →
Domestic producers aiming to supply that market need validated, standardised strains before scaling. Now, PGP Farmer says it is the only French operator positioned in the production of raw pharmaceutical materials for medical cannabis (MPUP).
The three-phase programme runs in partnership with Innexo BV, a Dutch applied research platform licensed to conduct cannabis trials, which will help provide the experimental infrastructure and analytical capability.
On the PGP Farmer side, the programme is led by Frédéric Lota, Chief Scientific Officer, a Doctor of Plant Biology with 15 years of applied R&D experience. Results will directly determine cultivation and processing protocols at the company’s 9-hectare Dordogne site, where a building permit has been granted, and long-term production capacity is projected to be 30 tonnes once operational.
“We do not select our varieties randomly,” said Brahim Sebart, Co-founder and Chief Executive Officer of PGP Farmer. “This POC tests 30 genotypes under rigorous conditions to retain only those that will guarantee patients a reliable, standardised and reproducible treatment.”
European demand for medical cannabis is growing at more than 20% per year, yet approximately 75% of EU flowers still arrive from outside the continent. Germany, the largest European market, imported close to 200 tonnes in 2025; France’s geographic proximity positions PGP Farmer as a natural candidate for that export demand.
The company has moved at pace since closing a €3 million funding round in February 2026 and contributing to the joint dossier submitted to the Haute Autorité de Santé in support of a full French medical cannabis rollout.
PGP Farmer is a sponsor of next week’s Cannabis Europa London 2026, and its progress in the rapidly evolving French medical cannabis market is set to be a key point of conversation.
26–27 May 2026 · Barbican, London Cannabis Europa Two days of policy, capital and clinical strategy at the Barbican — convening operators, investors, regulators and clinicians from across the European cannabis market.
Get Your Ticket Now →
The post PGP Farmer Launches 30-Variety Dutch Trial to Set Dordogne Production Blueprint appeared first on Business of Cannabis.
Continue reading...
